<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536014</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0337</org_study_id>
    <nct_id>NCT02536014</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Heart-rate Corrected QT(QTc) Interval Prolongation During Robotic-assisted Laparoscopic Radical Prostatectomy -Randomized Blind Clinical Trial-</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sympathetic activity could be increased during robot-assisted laparoscopic radical
      prostatectomy, which is performed in a steep trendelenburg position under CO2
      pneumoperitoneum.

      Stimulation of the sympathetic nervous system prolongs the QT interval and can increases the
      susceptibility to life threatening cardiac arrhythmias.

      Dexmedetomidine has sympatholytic effects and potential antiarrhythmic properties.
      Perioperative administration of dexmedetomidine is a potential preventive and treatment
      strategy for tachyarrhythmia. Thus the investigators decided to evaluate the effect of
      dexmedetomidine on heart-rate corrected QT interval during robot-assisted laparoscopic
      radical prostatectomy. Furthermore, the investigators evaluated the Tp-e, Tp-e/QT ratio and
      Tp-e/QTc ratio as well.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dexmedetomidine on heart-rate corrected QT(QTc) interval</measure>
    <time_frame>From pre-induciton until 60 min after the end of pneumoperitoneum</time_frame>
    <description>QTc intervals (msec) are recorded from pre-induction until 60 min after the end of pneumoperitoneum</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Robotic Surgery</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Dexmedetomidine infusion (0.3„éç/kg/hr) from anesthetic induction to the end of pneumoperitoneum</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline infusion during the same time period</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA class I-II

          2. Otaining written informed consent from the patients who were undergoing robot-
             assisted laparoscopic radical prostatectomy

        Exclusion Criteria:

          1. Emergency operation

          2. Cardiac disease (unstable angina, congestive heart failure, valvular heart disease)

          3. Ventricular conduction abnormality

          4. Prior pacemaker insertion

          5. Abnormal electrolyte values

          6. Patients who take antiarrythmic agent

          7. Hepatic or renal failure

          8. Drug hyperactivity

          9. Neurological or psychiatric illnesses
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>January 27, 2016</last_update_submitted>
  <last_update_submitted_qc>January 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>pneumoperitoneum</keyword>
  <keyword>trendelenburg position</keyword>
  <keyword>QTc interval</keyword>
  <keyword>Tp-e interval</keyword>
  <keyword>robotic prostatectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

